MX380701B - Transporte para atravesar la barrera hematoencefalica. - Google Patents

Transporte para atravesar la barrera hematoencefalica.

Info

Publication number
MX380701B
MX380701B MX2019006259A MX2019006259A MX380701B MX 380701 B MX380701 B MX 380701B MX 2019006259 A MX2019006259 A MX 2019006259A MX 2019006259 A MX2019006259 A MX 2019006259A MX 380701 B MX380701 B MX 380701B
Authority
MX
Mexico
Prior art keywords
brain barrier
blood
transport
cross
blood brain
Prior art date
Application number
MX2019006259A
Other languages
English (en)
Other versions
MX2019006259A (es
Inventor
Alain Tissot-Daguette
Bernd Bohrmann
Eduard Urich
Jens Niewoehner
Per-Ola Freskgard
Peter Maier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019006259A publication Critical patent/MX2019006259A/es
Publication of MX380701B publication Critical patent/MX380701B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a transportes a través de la barrera hematoencefálica que unen receptores sobre la barrera hematoencefálica (R/BBB) y métodos de uso de los mismos.
MX2019006259A 2012-08-29 2013-08-26 Transporte para atravesar la barrera hematoencefalica. MX380701B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12182181 2012-08-29
PCT/EP2013/067595 WO2014033074A1 (en) 2012-08-29 2013-08-26 Blood brain barrier shuttle

Publications (2)

Publication Number Publication Date
MX2019006259A MX2019006259A (es) 2019-09-23
MX380701B true MX380701B (es) 2025-03-12

Family

ID=46963437

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015002215A MX367126B (es) 2012-08-29 2013-08-26 Transporte para atravesar la barrera hematoencefálica.
MX2019006259A MX380701B (es) 2012-08-29 2013-08-26 Transporte para atravesar la barrera hematoencefalica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015002215A MX367126B (es) 2012-08-29 2013-08-26 Transporte para atravesar la barrera hematoencefálica.

Country Status (27)

Country Link
US (2) US20150322149A1 (es)
EP (2) EP2890712B1 (es)
JP (3) JP6219956B2 (es)
KR (4) KR20190121874A (es)
CN (2) CN104520329A (es)
AU (3) AU2013307406B2 (es)
BR (1) BR112015004512B1 (es)
CA (1) CA2879496C (es)
DK (1) DK2890712T3 (es)
ES (1) ES2733324T3 (es)
HK (1) HK1205521A1 (es)
HR (1) HRP20191153T1 (es)
HU (1) HUE045144T2 (es)
IL (2) IL237064A0 (es)
LT (1) LT2890712T (es)
MX (2) MX367126B (es)
MY (1) MY178542A (es)
NZ (1) NZ703585A (es)
PL (1) PL2890712T3 (es)
PT (1) PT2890712T (es)
RS (1) RS58928B1 (es)
RU (3) RU2711552C2 (es)
SG (2) SG11201500583PA (es)
SI (1) SI2890712T1 (es)
TR (1) TR201909156T4 (es)
WO (1) WO2014033074A1 (es)
ZA (1) ZA201500346B (es)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037811T2 (hu) 2011-10-28 2018-09-28 Prothena Biosciences Ltd Alfa-szinukleint felismerõ humanizált antitestek
CN108517010A (zh) 2012-01-27 2018-09-11 普罗典娜生物科学有限公司 识别α-突触核蛋白的人源化抗体
MY171761A (en) 2012-03-14 2019-10-28 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
KR20190121874A (ko) * 2012-08-29 2019-10-28 에프. 호프만-라 로슈 아게 혈액 뇌 장벽 셔틀
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015075011A1 (en) 2013-11-21 2015-05-28 F. Hoffmann-La Roche Ag ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE
JP6618912B2 (ja) 2013-12-20 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 改良された、組換えポリペプチド作製方法
AU2014368696A1 (en) 2013-12-20 2016-06-02 F. Hoffmann-La Roche Ag Humanized anti-Tau(pS422) antibodies and methods of use
ES2895752T3 (es) 2014-01-03 2022-02-22 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
CA2932547C (en) 2014-01-06 2023-05-23 F. Hoffmann-La Roche Ag Monovalent blood brain barrier shuttle modules
CA2944402A1 (en) * 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TWI726879B (zh) 2015-05-04 2021-05-11 美商Ｃｙｔｏｍｘ生物製藥公司 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN107949575B (zh) 2015-06-19 2022-03-08 卫材R&D管理有限公司 Cys80缀合型免疫球蛋白
PE20221007A1 (es) 2015-06-24 2022-06-15 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad disenada
EP3313890A1 (en) 2015-06-24 2018-05-02 H. Hoffnabb-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
CN113929779B (zh) 2015-06-24 2025-02-25 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
WO2017055542A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) * 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
IL287019B2 (en) * 2015-12-08 2025-10-01 Regeneron Pharma Preparations and methods for internalizing enzymes
MA45684A (fr) 2016-07-14 2019-05-22 Bioarctic Neuroscience Ab Protéine d'apport du cerveau
US10702589B2 (en) 2016-10-04 2020-07-07 Ann And Robert H. Lurie Children's Hospital Of Chicago Compositions and methods of treating neurological disorder and stress-induced conditions
US20190290750A1 (en) * 2016-12-02 2019-09-26 The Trustees Of The University Of Pennsylvania Dna antibody constructs for use against ebola virus
RU2711912C2 (ru) * 2016-12-15 2020-01-23 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН) Аптамер, проходящий через гематоэнцефалический барьер головного мозга мыши
WO2018117613A1 (ko) * 2016-12-19 2018-06-28 한미약품 주식회사 뇌 표적 지속성 단백질 결합체
KR102573622B1 (ko) 2016-12-26 2023-08-31 제이씨알 파마 가부시키가이샤 Bdnf를 포함하는 융합 단백질
EP3560955A4 (en) 2016-12-26 2020-12-23 Kyowa Kirin Co., Ltd. ANTIBODIES CAPABLE OF BINDING TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN
CN109983031B (zh) 2016-12-26 2022-11-25 Jcr制药股份有限公司 通过血脑屏障的新的抗人转铁蛋白受体抗体
KR102014066B1 (ko) 2017-01-06 2019-10-21 에이비엘바이오 주식회사 항 α-syn 항체 및 그 용도
AU2018212860A1 (en) * 2017-01-30 2019-08-15 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
ES2932759T3 (es) * 2017-02-17 2023-01-25 Denali Therapeutics Inc Polipéptidos de unión al receptor de transferrina diseñados
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
MX2019012381A (es) * 2017-05-18 2020-01-23 Hoffmann La Roche Reduccion de reaccion secundaria relacionada con la aplicacion de un anticuerpo terapeutico.
EP3635009B1 (en) 2017-06-07 2026-02-25 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
EP3665194A4 (en) * 2017-08-10 2021-07-07 Denali Therapeutics Inc. AFFINITY BASED METHODS FOR USING TRANSFERRIN RECEPTOR BINDING PROTEINS
EP3668886A2 (en) 2017-08-18 2020-06-24 Adrx, Inc. Tau aggregation peptide inhibitors
CN107410495B (zh) * 2017-08-24 2018-06-01 北京亦贝安生物医药科技有限公司 一种酸性乳糖酶和锌的复方制剂及其制备方法
CN107412747B (zh) * 2017-08-24 2018-05-22 北京亦贝安生物医药科技有限公司 一种含有乳铁蛋白和唾液酸的复方制剂
JP7403441B2 (ja) * 2017-09-14 2023-12-22 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
WO2019074892A1 (en) 2017-10-09 2019-04-18 Wisconsin Alumni Research Foundation ANTIBODIES TARGETING GLIOBLASTOME STRAIN TYPE CELLS AND METHODS OF USE
CA3080351A1 (en) 2017-11-02 2019-05-09 Ossianix, Inc. Improved tfr-selective binding peptides capable of crossing the blood brain barrier
BR112020011875A2 (pt) * 2017-12-14 2020-11-24 Abl Bio Inc. anticorpo biespecífico ao a-syn/igf1r e uso do mesmo
US10688191B2 (en) 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
KR102012448B1 (ko) * 2018-02-01 2019-08-20 (주)프론트바이오 트리메토벤자미드 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 신경병증 통증의 예방 또는 치료용 약학적 조성물
IL276464B2 (en) 2018-02-07 2026-01-01 Regeneron Pharma Methods and compositions for administering therapeutic protein
WO2019190293A1 (ko) * 2018-03-30 2019-10-03 한미약품 주식회사 뇌 표적 지속성 단백질 결합체, 이의 제조 방법, 및 이를 포함하는 조성물
MA52626A (fr) 2018-05-17 2021-03-24 Regeneron Pharma Anticorps anti-cd63, conjugués et leurs utilisations
US11753455B2 (en) 2018-06-21 2023-09-12 Novo Nordisk A/S Compounds for treatment of obesity
WO2020004490A1 (ja) 2018-06-26 2020-01-02 協和キリン株式会社 コンドロイチン硫酸プロテオグリカン－５に結合する抗体
CN112424358B (zh) 2018-06-26 2025-07-01 协和麒麟株式会社 与细胞粘附分子3结合的抗体
TW202017947A (zh) * 2018-08-22 2020-05-16 美商戴納立製藥公司 抗her2 多肽及其使用方法
CN112771165A (zh) * 2018-08-30 2021-05-07 (株)纳斯摩仕 通过血脑屏障的核酸适配体及其应用
WO2020056327A1 (en) 2018-09-14 2020-03-19 Ossianix, Inc. Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
KR102692543B1 (ko) 2018-10-26 2024-08-07 재단법인 목암생명과학연구소 Ids를 포함하는 융합 단백질 및 이의 용도
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
CA3130546A1 (en) 2019-03-29 2020-10-08 Tilman Schlothauer Method for the generation of an fcrn expressing cell by targeted integration of multiple expression cassettes in a defined organization
CN113801219A (zh) * 2019-05-23 2021-12-17 江苏豪思睦可生物科技有限公司 一种转铁蛋白的制备方法及包含转铁蛋白的组合物和应用
JP7572977B2 (ja) 2019-06-19 2024-10-24 エフ． ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットの標的化組込みによって多価の多重特異性抗体発現細胞を作製するための方法
WO2020254352A1 (en) 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
WO2021020618A1 (ko) * 2019-07-30 2021-02-04 (주)프론트바이오 트리메토벤자미드 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 신경병증 통증의 예방 또는 치료용 약학적 조성물
EP4028048A1 (en) * 2019-09-09 2022-07-20 F. Hoffmann-La Roche AG Glucocerebrosidase mutants
KR102247568B1 (ko) 2019-10-11 2021-05-04 재단법인 대구경북첨단의료산업진흥재단 집속초음파 조사 시스템 및 집속초음파를 이용한 혈액뇌장벽 개방 조절 방법
AU2020411480B2 (en) 2019-12-23 2023-12-21 Denali Therapeutics Inc. Progranulin variants
TW202140513A (zh) 2020-02-22 2021-11-01 日商Ｊｃｒ製藥股份有限公司 人類運鐵蛋白受體結合肽
EP4110794A1 (en) 2020-02-25 2023-01-04 Vib Vzw Leucine-rich repeat kinase 2 allosteric modulators
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
US20240141027A1 (en) 2021-06-11 2024-05-02 Bioarctic Ab Bispecific binding molecule
EP4373853A4 (en) * 2021-07-21 2025-07-02 Icahn School Med Mount Sinai ANTI-FSH ANTIBODIES AGAINST NEURODEGENERATIVE DISEASES
CA3228449A1 (en) 2021-08-19 2023-02-23 Peptidream Inc. Human transferrin receptor binding peptide
CA3229962A1 (en) 2021-08-24 2023-03-02 Peptidream Inc. Human transferrin receptor-binding antibody-peptide conjugate
WO2023034409A1 (en) 2021-09-01 2023-03-09 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
JP2024536278A (ja) * 2021-10-01 2024-10-04 ナイベック カンパニー リミテッド 血液脳関門透過用ペプチド及びこの用途
WO2023128702A1 (ko) * 2021-12-31 2023-07-06 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
KR102575322B1 (ko) * 2021-12-31 2023-09-08 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
JP2025514645A (ja) 2022-04-12 2025-05-09 エフ． ホフマン－ラ ロシュ アーゲー 中枢神経系に対して標的化された融合タンパク質
EP4551600A1 (en) 2022-07-04 2025-05-14 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
CR20250044A (es) * 2022-08-08 2025-03-05 Lilly Co Eli Proteínas y conjugados de unión al receptor de transferrina listado de secuencias
WO2024080843A1 (ko) * 2022-10-14 2024-04-18 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
KR20240067001A (ko) * 2022-10-28 2024-05-16 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
CN120603851A (zh) 2023-01-30 2025-09-05 伊萨尔生物科学有限责任公司 用于治疗神经退行性疾病的人抗trem2抗体
TW202434613A (zh) 2023-02-17 2024-09-01 日商肽夢想股份有限公司 人類運鐵蛋白受體結合肽
KR20250162888A (ko) 2023-03-24 2025-11-19 바이오악틱 에이비 인간 트랜스페린 수용체 htfr1의 프로테아제-유사 도메인에 결합하는 이중특이적 항체
CN121548587A (zh) 2023-07-24 2026-02-17 豪夫迈·罗氏有限公司 多特异性抗体
AU2024322991A1 (en) 2023-08-09 2026-01-08 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
WO2025054461A1 (en) * 2023-09-08 2025-03-13 California Institute Of Technology Ester derivatives of binders targeting ca-iv
WO2025137213A1 (en) 2023-12-20 2025-06-26 Denali Therapeutics Inc. Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof
US20250388664A1 (en) 2024-06-20 2025-12-25 Bioarctic Ab Bispecific binding molecule
US20260035475A1 (en) 2024-06-20 2026-02-05 Bioarctic Ab Stabilized binding molecule

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
DK1409654T3 (da) * 1999-06-16 2008-12-08 Boston Biomedical Res Inst Immunologisk styring af beta-amyloid-niveauer in vivo
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US6849032B2 (en) * 2002-11-20 2005-02-01 Fitness Botics, Inc. Exercise apparatus simulating skating motions
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
NZ568241A (en) * 2005-12-12 2011-08-26 Hoffmann La Roche Antibodies against amyloid beta 4 with glycosylation in the variable region
DE102006013531A1 (de) * 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
BRPI0919382A2 (pt) * 2008-09-26 2016-01-05 Roche Glycart Ag anticorpos bi-específicos anti-egfr/anti-igf-1r
PE20120591A1 (es) * 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
CN110251668A (zh) * 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
KR20190121874A (ko) * 2012-08-29 2019-10-28 에프. 호프만-라 로슈 아게 혈액 뇌 장벽 셔틀

Also Published As

Publication number Publication date
JP2015528452A (ja) 2015-09-28
KR20170041289A (ko) 2017-04-14
TR201909156T4 (tr) 2019-07-22
CN109053901A (zh) 2018-12-21
CA2879496C (en) 2024-01-09
AU2018203400A1 (en) 2018-06-07
DK2890712T3 (da) 2019-07-08
PT2890712T (pt) 2019-06-28
KR102036262B1 (ko) 2019-10-24
WO2014033074A1 (en) 2014-03-06
ES2733324T3 (es) 2019-11-28
EP2890712B1 (en) 2019-05-01
HUE045144T2 (hu) 2019-12-30
CN104520329A (zh) 2015-04-15
RS58928B1 (sr) 2019-08-30
KR20180088492A (ko) 2018-08-03
BR112015004512B1 (pt) 2021-08-24
RU2663120C2 (ru) 2018-08-01
MY178542A (en) 2020-10-15
SI2890712T1 (sl) 2019-08-30
RU2019142838A3 (es) 2021-06-21
EP3315514C0 (en) 2025-06-18
ZA201500346B (en) 2016-01-27
US20150322149A1 (en) 2015-11-12
JP6219956B2 (ja) 2017-10-25
RU2015111093A (ru) 2016-10-20
NZ703585A (en) 2018-03-23
JP2020007352A (ja) 2020-01-16
PL2890712T3 (pl) 2019-09-30
JP6889218B2 (ja) 2021-06-18
CA2879496A1 (en) 2014-03-06
BR112015004512A2 (pt) 2017-11-07
EP3315514A1 (en) 2018-05-02
RU2754794C2 (ru) 2021-09-07
HRP20191153T1 (hr) 2019-10-04
MX367126B (es) 2019-08-06
KR20190121874A (ko) 2019-10-28
MX2015002215A (es) 2015-05-08
JP2018029602A (ja) 2018-03-01
SG10201702702VA (en) 2017-06-29
AU2013307406A1 (en) 2015-01-29
IL237064A0 (en) 2015-03-31
AU2013307406B2 (en) 2018-03-15
IL278872A (en) 2021-01-31
AU2020210286A1 (en) 2020-08-20
US20190276530A1 (en) 2019-09-12
RU2018127006A (ru) 2019-03-14
KR101885044B1 (ko) 2018-08-02
HK1205521A1 (en) 2015-12-18
KR20150039798A (ko) 2015-04-13
EP3315514B1 (en) 2025-06-18
AU2018203400B2 (en) 2020-05-28
LT2890712T (lt) 2019-07-25
RU2018127006A3 (es) 2019-03-14
SG11201500583PA (en) 2015-04-29
RU2711552C2 (ru) 2020-01-17
MX2019006259A (es) 2019-09-23
EP2890712A1 (en) 2015-07-08
RU2019142838A (ru) 2021-06-21

Similar Documents

Publication Publication Date Title
MX380701B (es) Transporte para atravesar la barrera hematoencefalica.
JOP20180102B1 (ar) مركب صيدلاني
UY34885A (es) Proteínas de unión anti-mesotelina
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
BR112014017749A2 (pt) Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
CU24336B1 (es) Compuestos de imidazopirrolidinona
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
CR20140429A (es) Complejos de polielectrolitos para mejoramiento de un biocida
BR302013000808S1 (pt) Configuração aplicada em cordão.
IL235585B (en) Ha binding agents, compositions comprising same and uses thereof
CL2015001157A1 (es) Composiciones y métodos para tratar proteinopatías.
EP2714059A4 (en) TREATMENT OF PAIN USING PLACENTARIAN STEM CELLS
BR302012006035S1 (pt) Configuracao aplicada em lanterna traseira combinada para automovel
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
UY34751A (es) ?composición de pienso para reducir la metanogénesis en rumiantes?
IL238398B (en) Lyophilized preparations of melphalan flupenamide
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
BR302012004766S1 (pt) Configuracao aplicada em injetor médico
UY34842A (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
UY34553A (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo
CL2014002817A1 (es) Compuesto monoclorhidrato de anamorelina que tiene contenido controlado de cloruro; composicion que lo comprende; procedimiento de preparacion del compuesto.
EA201492280A1 (ru) Стабильный состав пексиганана